Minetto, P., Riva, C., Carminati, E., Zecchetti, G., Puglisi, F., Nurra, C., Cea, M., Lemoli, R., Guolo, F. (2025). The presence of secondary type or DNMT3A mutations does not affect prognosis in NPM1 mutated AML treated with intensified fludarabine-high dose cytarabine and idarubicine (FLAI) induction regimen.. Blood. https://doi.org/10.1182/blood-2025-1625